Azithromycin uptake may reduce postcesarean infections - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Azithromycin uptake may reduce postcesarean infections

  • By

  • Andrea Surnit

  • September 30, 2026

  • 4 min

Share

Azithromycin uptake may reduce postcesarean infections

Overview

A retrospective analysis of nearly 1.7 million deliveries indicates that the use of adjunctive azithromycin during unscheduled cesarean deliveries increased significantly post-2016, leading to a 2-percentage-point reduction in postpartum infections.

Background

Postcesarean infections remain a significant concern in obstetric care, impacting maternal health outcomes. The introduction of adjunctive azithromycin has been shown to reduce infection rates in clinical trials.

Data Highlights

Delivery TypeAzithromycin Use Pre-TrialAzithromycin Use Post-TrialPostpartum Infection Rate Pre-TrialPostpartum Infection Rate Post-Trial
Cesarean2%40%9%8%
Vaginal0.01%0.04%2%3%

Key Findings

  • Perioperative azithromycin use among cesarean deliveries increased from 2% to 40% following the publication of trial evidence.
  • Postpartum infection rates after cesarean delivery decreased from 9% to 8% during the same period.
  • Components of the composite infection outcome, including endometritis and sepsis, declined following cesarean delivery.
  • Azithromycin use remained low in vaginal deliveries, increasing only slightly from 0.01% to 0.04%.
  • The adjusted difference-in-differences estimate indicated a 20% relative decrease in postpartum infections associated with azithromycin use.
  • Fewer than 50% of cesarean delivery patients received azithromycin post-publication, compared to 100% in the trial.

Clinical Implications

The increase in azithromycin use among cesarean deliveries suggests a shift towards incorporating evidence-based practices in obstetric care. However, the incomplete adoption highlights the need for further efforts to standardize antibiotic prophylaxis in clinical settings.

Conclusion

The study demonstrates a significant increase in azithromycin use and a corresponding decrease in postpartum infections following cesarean deliveries, although the real-world impact is less pronounced than in clinical trials.

Related Resources & Content

  1. Freret TS, et al., JAMA, 2023 -- Adoption of Adjunctive Azithromycin for Unscheduled Cesarean Delivery and Postpartum Infections
  2. Tita ATN, et al., JAMA, 2023 -- Editorial on Azithromycin Use in Cesarean Deliveries
  3. C/SOAP Trial, NEJM, 2016 -- Adjunctive Azithromycin Prophylaxis for Cesarean Delivery
  4. JAMA Network Open — Prenatal Azithromycin Exposure and Risk of Neurodevelopmental Disorders in Children
  5. JAMA Network Open — Infant Growth After Mass Administration of Azithromycin: Secondary Outcomes of a Cluster Randomized Clinical
  6. MDSpire News — Should Antibiotics Be Added After Episiotomy?
  7. MDSpire News — Antibiotics Cut SSI Risk in Pediatric Surgery
  8. Antimicrobial Prophylaxis in Surgery - ASHP Surgical Prophylaxis Guidelines
  9. Adjunctive Azithromycin Prophylaxis for Cesarean Delivery - PMC
  10. Adoption of Adjunctive Azithromycin for Unscheduled Cesarean Delivery and Postpartum Infections | Reproductive Health | JAMA | JAMA Network

Original Source(s)

Related Content